Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer save search
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE S | $136.78 -1.17% 48K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
Novartis presents new data in breast and prostate cancer at ESMO
Published: 2022-08-30 (Crawled : 06:00) - globenewswire.com
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -0.3%
H: 0.02%
C: -1.51%
novartis cancer prostate cancer
Fallopian Tube Cancer Therapeutics Market Research Report by Technavio predicts USD 628.28 Mn growth | North America to have a significant share
Published: 2022-08-29 (Crawled : 15:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: -2.7%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: 0.39%
H: 0.05%
C: -0.9%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.33%
H: 0.45%
C: 0.09%
BAX | $39.415 -1.56% 640K
|
Health Technology
|
| O: -0.65%
H: 0.92%
C: 0.33%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: -0.11%
H: 0.38%
C: -0.36%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: -0.75%
H: 0.92%
C: 0.23%
america research tube report therapeutics cancer growth market
Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight
Published: 2022-08-29 (Crawled : 14:20) - biospace.com/
ILMN | $117.87 -2.72% 630K
|
Health Technology
|
| O: -0.83%
H: 3.37%
C: 3.2%
genomics cancer
Global Gynecological Cancer Drugs Market Report 2022: Featuring Key Players Apotex, Astrazeneca, GlaxoSmithKline, Merck & Others
Published: 2022-08-29 (Crawled : 13:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.7%
H: 0.49%
C: -1.02%
BMY | $48.35 -0.33% 2.1M
|
Health Technology
|
| O: -1.81%
H: 0.01%
C: -4.51%
global report cancer market
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
Published: 2022-08-29 (Crawled : 12:00) - biospace.com/
MRK | $125.715 -0.38% 1.4M
|
Health Technology
|
| O: -0.48%
H: 0.19%
C: -1.4%
cancer
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Published: 2022-08-25 (Crawled : 11:00) - biospace.com/
FNCTF | $11.128 580
|
Communications
| Email alert
Add to watchlist
lynparza treatment risk japan approved cancer her2- her2
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
Published: 2022-08-24 (Crawled : 16:00) - biospace.com/
BPMC | $86.355 1.38% 66K
|
Health Technology
|
| O: 0.17%
H: 6.36%
C: 4.29%
disease cancer study
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
Published: 2022-08-24 (Crawled : 13:20) - biospace.com/
SLS | $1.34 430K
|
Health Technology
|
| O: -0.6%
H: 3.03%
C: 2.42%
gfh009 preclinical life cancer growth prostate cancer in vitro
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
Published: 2022-08-24 (Crawled : 12:20) - globenewswire.com
OCX | $2.5 -1.19% 81K
|
Health Technology
|
| O: -1.09%
H: 3.44%
C: 1.94%
response bladder therapy cancer publication
Oncolyze, a Company Aiming to Treat Cancer by Exploding Cancer Cells, is Now Accepting Investments. Own a Piece in the Future of Cancer Treatment.
Published: 2022-08-23 (Crawled : 17:00) - biospace.com/
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
cancer
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight
Published: 2022-08-23 (Crawled : 16:00) - prnewswire.com
IBRX | $5.04 -3.82% 940K
|
Manufacturing
|
| O: 0.27%
H: 6.27%
C: 4.0%
URGN | $14.43 -4.44% 71K
|
Health Technology
|
| O: 0.64%
H: 0.32%
C: -0.63%
TARA | $2.735 -8.83% 66K
|
Health Technology
|
| O: -0.38%
H: 3.83%
C: 1.73%
INCY | $53.88 0.84% 230K
|
Health Technology
|
| O: -0.49%
H: 0.36%
C: -0.33%
companies trial bladder cancer
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
ERAS | $1.965 -1.75% 170K
|
|
| O: 0.83%
H: 6.21%
C: 4.22%
research collaboration cancer
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
IMNM | $18.52 -1.75% 180K
|
Health Technology
|
| O: -3.25%
H: 10.82%
C: 9.51%
immunology cancer publication
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
Published: 2022-08-23 (Crawled : 13:00) - biospace.com/
HALB | $0.0084 1.6M
|
n/a
|
| O: 0.0%
H: 20.37%
C: 0.0%
t-cell control cancer
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
CANF | $2.21 6.76% 3.2K
|
Health Technology
|
| O: 3.37%
H: 6.52%
C: 3.65%
treatment drug liver approved cancer a3ar namodenoson
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
Published: 2022-08-23 (Crawled : 12:00) - immatics.com
IMTX | $10.325 -0.72% 60K
|
Health Technology
|
| O: -0.18%
H: 5.01%
C: 4.04%
ima203 actengine candidate cancer
Prana Thoracic Announces That Its Subsidiary Receives $3 Million CPRIT Grant to Develop a Minimally Invasive Device for Early Interception of Lung Cancer
Published: 2022-08-22 (Crawled : 22:00) - biospace.com/
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
lung device grant cancer
Global Colorectal Cancer Market to Grow to $24.07 Billion by 2028 from $18.61 Billion in 2022
Published: 2022-08-22 (Crawled : 16:00) - prnewswire.com
BRKR | $84.0 -2.04% 180K
|
Health Technology
|
| O: -0.08%
H: 1.09%
C: -1.22%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: -0.35%
H: 0.5%
C: -1.23%
VNRX | $0.64 -5.72% 52K
|
Health Technology
|
| O: -3.19%
H: 1.37%
C: -12.09%
global cancer market
Head And Neck Cancer Diagnostics Market Size to Grow by USD 4.22 billion, Increasing Incidences of Head and Neck Cancers to Drive Growth - Technavio
Published: 2022-08-22 (Crawled : 07:00) - prnewswire.com
RYLPF | $20.515 7K
|
Health Technology
|
| O: -3.94%
H: 0.0%
C: 0.0%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 0.08%
H: 0.49%
C: -1.15%
diagnostics cancer growth market
Gainers vs Losers
| 51% | 49% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.